GSE171964
CITE-seq of 6 patients treated with the Pfizer BioNTech BNT162b2 mRNA vaccine
Purpose: To understand the single cell landscape of patients treated with the BNT162b2 mRNA vaccine Overall design: Methods: peripheral blood was isolated from 6 volunteers before, 24 or 48 hours, and 7 days after the primary and secondary immunization